CME/CE

The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, muscle degeneration, adipogenesis, and fibrosis. You’ll review the latest clinical trial data and real-world evidence for novel therapies and understand where they may fit within complex, existing treatment regimens. Through practical case scenarios, the program highlights how to integrate new approaches into polypharmacy strategies. Stay ahead of the science and get ready to apply it.

On-demand webcast on the pathophysiology of chronic kidney disease (CKD) and expert-informed strategies to help nephrology take the helm in integrating the latest data to provide guideline-concordant care to patients with CKD.

This activity focuses on optimizing multidisciplinary strategies in the guideline-driven management of cervical and endometrial cancers. Dr. Brian Slomovitz presents recent and emerging clinical data for immunotherapy-based treatment strategies, explores the role of screening and biomarkers, and emphasizes interprofessional collaboration across oncology specialties. Case-based learning contextualizes key concepts and highlights guideline-concordant care for patients with cervical and endometrial cancers.

In this expert commentary, Dr. Narayanaswami highlights key messages from the Prova Education satellite symposium held at the 2025 AANEM Meeting in San Francisco. The discussion centers on the clinical application of FcRn antagonists in gMG, reviewing the rationale for FcRn blockade, approved FcRN antagonists, and pivotal clinical trial data. Differences in therapy onset, duration, administration, and tolerability are outlined, along with considerations for treatment selection based on antibody profiles and diagnostic criteria. Practical insights address use in special populations, coordination with plasma exchange, and vaccination timing, offering clinicians a concise synthesis of the symposium’s clinical guidance.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.